Compound KTI-2338 Inhibits ACVR1 Receptor Signaling in Fibrodysplasia Ossificans Progressiva.

Area of Science:

• Genetics and Molecular Biology
• Rare Disease Research
• Pharmacology

Background:

• Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disorder causing progressive immobilization due to heterotopic ossification.
• A common FOP genetic variant involves a constitutively overactive ALK2 receptor, leading to aberrant SMAD1/5/9 pathway activation.
• This dysregulated signaling drives abnormal bone formation, even in response to non-canonical ligands like Activin A.

Purpose of the Study:

• To characterize the in vitro effects of a novel, selective ALK2 kinase inhibitor, KTI-2338.
• To evaluate KTI-2338's potential therapeutic impact on FOP's underlying pathological mechanisms.

Main Methods:

• Cultured human FOP and control dermal fibroblasts.
• Treated cells with osteogenic medium, with and without KTI-2338.
• Assessed transdifferentiation into osteoblast-like cells by measuring osteogenic markers and pSMAD1/5/9 levels.

Main Results:

• KTI-2338 demonstrated inhibition of aberrant Activin A signaling and ALK2 receptor sensitization.
• Reduced expression of osteogenic markers and phosphorylated SMAD1/5/9 (pSMAD1/5/9) was observed.
• Alizarin Red staining indicated significantly reduced mineralization in KTI-2338 treated cells.

Conclusions:

• Kinase inhibitor KTI-2338 effectively disrupts the pathological signaling pathways in FOP.
• These findings suggest KTI-2338 is a promising therapeutic candidate for Fibrodysplasia Ossificans Progressiva.
• Further investigation into KTI-2338 as a treatment option for FOP is warranted.